Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study
Marta Bravo Peña(Institut Català d'Oncologia), Alberto Mussetti(Duran i Reynals Hospital), Jacopo Mariotti(Istituti di Ricovero e Cura a Carattere Scientifico), Pascual Balsalobre(Grupo Español de Trasplante Hematopoyético y Terapia Celular), Giulia Losi(University of Pavia), Yasmina Serroukh(Erasmus MC), C Solano(Hospital Clínico Universitario de Valencia), Mi Kwon(Keimyung University), Carmen Albo López(Complexo Hospitalario Universitario A Coruña), Nicole Fabbri(Institut Català d'Oncologia), Carlos Panizo, Víctor Noriega(Complexo Hospitalario Universitario A Coruña), María Jesús Pascual-Cascón(Hospital Regional Universitario de Málaga), David Qualls(Memorial Sloan Kettering Cancer Center), Jennifer L. Crombie(Dana-Farber Cancer Institute), Raquel Saldaña(Hospital Jerez Puerta del Sur), Vı́ctor Navarro(Vall d'Hebron Institut de Recerca), Montserrat Rovira(Hospital Clínic de Barcelona), Inmaculada Heras(Hospital General Universitario Morales Meseguer), Manuel Guerreiro(IPO Porto), Christopher McKinnely(Fiona Stanley Hospital), David Valcárcel(Vall d'Hebron Hospital Universitari), Leyre Bento(Health Research Institute of the Balearic Islands), Lucía Lopez-Corral(Instituto de Investigación Biomédica de Salamanca), Manuel Jurado(Hospital Universitario Virgen de las Nieves), Ángel Serna(Vall d'Hebron Hospital Universitari), Andres Sanchez-Salinas(Hospital Universitario Virgen de la Arrixaca), Ya-Ting Hsu(National Cheng Kung University Hospital), P. Armand(Dana-Farber Cancer Institute), Maria Calbacho(Hospital Universitario 12 De Octubre), A. Sureda(Institut Català d'Oncologia)
Cited by 1
Related Papers
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
|Blood|2019|187
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
|Blood|2024|132
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
|Haematologica|2022|131
The treatment of Burkitt lymphoma in adults
|Blood|2020|105